Immune response to HSP70-HBcAg(18-27) complex in HBV transgenic mice.

Huai-dong HU; Peng HU; Guo-lin Chen; Ming-li Peng; Min Chen; Hong Ren

Return

Immune response to HSP70-HBcAg(18-27) complex in HBV transgenic mice.

Author: Huai-dong HU ¹ ; Peng HU ; Guo-lin CHEN ; Ming-li PENG ; Min CHEN ; Hong REN
Author Information

1. Key Laboratory of Molecular Biology for Infectious Diseases, PRC Ministry of Education, Institute for Viral Hepatitis, Chongqing University of Medical Sciences, Chongqing 400010, China.
Publication Type:Journal Article
MeSH: Animals; Female; HSP70 Heat-Shock Proteins; immunology; Hepatitis B Core Antigens; immunology; Hepatitis B virus; genetics; immunology; Male; Mice; Mice, Transgenic; Spleen; immunology; T-Lymphocytes, Cytotoxic; immunology
From: Chinese Journal of Hepatology 2007;15(1):28-31
CountryChina
Language:Chinese
Abstract:
OBJECTIVESTo study the cellular immune response to HSP70-HBcAg(18-27) complex in HBV transgenic mice.
METHODHSP70-HBcAg(18-27) complex was reconstituted in vitro, then it was injected into HBV transgenic mice to observe the cellular immune response. At the same time, we investigated whether HSP70-HBcAg(18-27) complex could generate antigen specific cytotoxic T lymphocyte responses in spleen cells.
RESULTSOur results demonstrated that HSP70-HBcAg(18-27) complex increased levels of CD4+ and CD8+ T cells in the spleens and peripheral blood of HBV transgenic mice, and the complex also activated dendritic and natural killer cells.
CONCLUSIONHSP70-HBcAg(18-27) complex has an immunological antigenicity in raising the immunoresponse to chronic HBV infection in HBV transgenic mice. HSP70-HBcAg(18-27) complex might be considered as a candidate for further studies on its role as a therapeutic vaccine against chronic HBV infection in humans.